Disc Medicine Company Leadership
| IRON Stock | 53.74 0.91 1.72% |
Disc Medicine's insiders are aggressively selling. The analysis of the overall insider sentiment regarding Disc Medicine suggests that virtually all insiders are panicking. Disc Medicine employs about 84 people. The company is managed by 14 executives with a total tenure of roughly 196 years, averaging almost 14.0 years of service per executive, having 6.0 employees per reported executive.
Insider Sentiment 0
Mostly Selling
Selling | Buying |
Latest Trades
| 2025-03-12 | Mona Ashiya | Disposed 83182 @ 54.45 | View | ||
| 2025-03-10 | Mona Ashiya | Disposed 202146 @ 54.29 | View | ||
| 2025-02-18 | Pamela Stephenson | Disposed 3137 @ 54.58 | View | ||
| 2025-02-03 | Rahul Khara | Disposed 7500 @ 55.54 | View | ||
| 2025-01-02 | Rahul Khara | Disposed 7500 @ 62.75 | View | ||
| 2024-12-30 | John D Quisel | Disposed 13012 @ 61.95 | View | ||
| 2024-12-23 | John D Quisel | Disposed 19820 @ 63.14 | View | ||
| 2024-12-16 | John D Quisel | Disposed 12791 @ 66.01 | View | ||
| 2024-12-02 | William Richard White | Disposed 1957 @ 64.63 | View | ||
| 2024-11-25 | William Jacob Savage | Disposed 14183 @ 65.45 | View | ||
| 2024-11-15 | William Jacob Savage | Disposed 9158 @ 59.64 | View | ||
| 2024-11-04 | William Richard White | Disposed 7136 @ 58.61 | View | ||
| 2024-11-01 | William Richard White | Disposed 201 @ 46.37 | View | ||
| 2024-10-01 | William Richard White | Disposed 201 @ 51.31 | View | ||
| 2024-08-01 | William Richard White | Disposed 201 @ 43.44 | View | ||
| 2024-04-11 | William Richard White | Disposed 2560 @ 31.8 | View |
Monitoring Disc Medicine's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Disc |
Disc Medicine Management Team Effectiveness
The company has return on total asset (ROA) of (0.1875) % which means that it has lost $0.1875 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2773) %, meaning that it created substantial loss on money invested by shareholders. Disc Medicine's management efficiency ratios could be used to measure how well Disc Medicine manages its routine affairs as well as how well it operates its assets and liabilities. As of the 20th of March 2025, Return On Tangible Assets is likely to drop to -0.2. In addition to that, Return On Capital Employed is likely to drop to -0.25. As of the 20th of March 2025, Other Assets is likely to grow to about 217.3 K, while Total Assets are likely to drop about 281.5 M.As of the 20th of March 2025, Common Stock Shares Outstanding is likely to drop to about 15.3 M. In addition to that, Net Loss is likely to drop to about (34 M)
Disc Medicine Workforce Comparison
Disc Medicine is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 2,375. Disc Medicine holds roughly 84.0 in number of employees claiming about 4% of equities under Health Care industry.
Disc Medicine Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Disc Medicine insiders, such as employees or executives, is commonly permitted as long as it does not rely on Disc Medicine's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Disc Medicine insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2025-03-01 | 0.3636 | 16 | 44 | 540,573 | 672,522 |
| 2024-12-01 | 0.3158 | 12 | 38 | 88,459 | 166,918 |
| 2024-09-01 | 0.3125 | 5 | 16 | 5,359 | 10,718 |
| 2024-06-01 | 1.5 | 21 | 14 | 902,146 | 31,306 |
| 2024-03-01 | 1.75 | 14 | 8 | 521,497 | 328,657 |
| 2022-12-01 | 2.0 | 2 | 1 | 2,718,023 | 0.00 |
Disc Medicine Notable Stakeholders
A Disc Medicine stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Disc Medicine often face trade-offs trying to please all of them. Disc Medicine's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Disc Medicine's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| ChB MB | Founder Board | Profile | |
| Esq JD | President CEO | Profile | |
| Donald Nicholson | Independent Chairman | Profile | |
| Jonathan Yu | Chief Officer | Profile | |
| Rahul Kaushik | Chief Officer | Profile | |
| Joanne CPA | Chief Officer | Profile | |
| William MD | Chief Officer | Profile | |
| Pamela MPH | Chief Officer | Profile | |
| Jean CPA | Chief Officer | Profile | |
| Hua Yang | Senior Pharmacology | Profile | |
| Jean Franchi | Chief Officer | Profile | |
| Srikanth Venkatraman | Senior Chemistry | Profile | |
| Jonathan MBA | Chief Officer | Profile | |
| PharmD JD | Compliance Counsel | Profile |
About Disc Medicine Management Performance
The success or failure of an entity such as Disc Medicine often depends on how effective the management is. Disc Medicine management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Disc management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Disc management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.19) | (0.20) | |
| Return On Capital Employed | (0.24) | (0.25) | |
| Return On Assets | (0.19) | (0.20) | |
| Return On Equity | (0.25) | (0.24) |
Disc Medicine Workforce Analysis
Traditionally, organizations such as Disc Medicine use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Disc Medicine within its industry.Disc Medicine Manpower Efficiency
Return on Disc Medicine Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.3M | |
| Net Loss Per Executive | 7.8M | |
| Working Capital Per Employee | 5.6M | |
| Working Capital Per Executive | 33.6M |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Disc Medicine. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in Disc Stock, please use our How to Invest in Disc Medicine guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Disc Medicine. If investors know Disc will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Disc Medicine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Disc Medicine is measured differently than its book value, which is the value of Disc that is recorded on the company's balance sheet. Investors also form their own opinion of Disc Medicine's value that differs from its market value or its book value, called intrinsic value, which is Disc Medicine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Disc Medicine's market value can be influenced by many factors that don't directly affect Disc Medicine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Disc Medicine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Disc Medicine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Disc Medicine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.